verified the applicant's claim that the new drug application (NDA) for VALTREX® (NDA 20–487) was initially submitted on June 23, 1994.

3. The date the human drug was approved: June 23, 1995. FDA has verified the applicant's claim that NDA 20–487 was approved on June 23, 1995.

This determination of the regulatory review period establishes the maximum potential length of a patent extension. However, the U.S. Patent and Trademark Office applies several statutory limitations in its calculations of the actual period for patent extension. In its application for patent extension, this applicant seeks 1,052 days of patent term extension.

Anyone with knowledge that any of the dates as published is incorrect may, on or before February 5, 1996, submit to the Dockets Management Branch (address above) written comments and ask for a redetermination. Furthermore, any interested person may petition FDA, on or before June 5, 1996, for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period. To meet its burden, the petition must contain sufficient facts to merit an FDA investigation. (See H. Rept. 857, part 1, 98th Cong., 2d sess., pp. 41-42, 1984.) Petitions should be in the format specified in 21 CFR 10.30.

Comments and petitions should be submitted to the Dockets Management Branch (address above) in three copies (except that individuals may submit single copies) and identified with the docket number found in brackets in the heading of this document. Comments and petitions may be seen in the Dockets Management Branch between 9 a.m. and 4 p.m., Monday through Friday.

Dated: November 30, 1995.

Stuart L. Nightingale,

Associate Commissioner for Health Affairs. [FR Doc. 95–29809 Filed 12–6–95; 8:45 am] BILLING CODE 4160–01–F

[Docket No. 95E-0302]

Determination of Regulatory Review Period for Purposes of Patent Extension; ULTANETM

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) has determined the regulatory review period for ULTANE[™] and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product. **ADDRESSES:** Written comments and petitions should be directed to the Dockets Management Branch (HFA– 305), Food and Drug Administration, rm. 1–23, 12420 Parklawn Dr., Rockville, MD 20857.

FOR FURTHER INFORMATION CONTACT: Brain J. Malkin, Office of Health Affairs (HFY–20), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–443–1382.

SUPPLEMENTARY INFORMATION: The Drug Price Competition and Patent Term Restoration Act of 1984 (Pub. L. 98-417) and the Generic Animal Drug and Patent Term Restoration Act (Pub. L. 100–670) generally provide that a patent may be extended for a period of up to 5 years so long as the patented item (human drug product, animal drug product, medical device, food additive, or color additive) was subject to regulatory review by FDA before the item was marketed. Under these acts, a product's regulatory review period forms the basis for determining the amount of extension an applicant may receive.

A regulatory review period consists of two periods of time: A testing phase and an approval phase. For human drug products, the testing phase begins when the exemption to permit the clinical investigations of the drug becomes effective and runs until the approval phase begins. The approval phase starts with the initial submission of an application to market the human drug product and continues until FDA grants permission to market the drug product. Although only a portion of a regulatory review period may count toward the actual amount of extension that the Commissioner of Patents and Trademarks may award (for example, half the testing phase must be subtracted as well as any time that may have occurred before the patent was issued), FDA's determination of the length of a regulatory review period for a human drug product will include all of the testing phase and approval phase as specified in 35 U.S.C. 156(g)(1)(B).

FDA recently approved for marketing the human drug product ULTANETM (sevoflurane). ULTANETM is indicated for induction and maintenance of general anesthesia in adult and pediatric patients for inpatient and outpatient surgery. Subsequent to this approval, the Patent and Trademark Office received a patent term restoration application for ULTANETM (U.S. Patent

No. 4,250,334) from Baxter International, Inc., and the Patent and Trademark Office requested FDA's assistance in determining this patent's eligibility for patent term restoration. In a letter dated September 25, 1995, FDA advised the Patent and Trademark Office that this human drug product had undergone a regulatory review period and that the approval of ULTANETM represented the first permitted commercial marketing or use of the product. Shortly thereafter, the Patent and Trademark Office requested that FDA determine the product's regulatory review period.

FDA has determined that the applicable regulatory review period for ULTANE[™] is 3,418 days. Of this time, 3,086 days occurred during the testing phase of the regulatory review period, while 332 days occurred during the approval phase. These periods of time were derived from the following dates:

1. The date an exemption under section 505(i) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(i)) became effective: January 29, 1986. The applicant claims January 10, 1986, as the date the investigational new drug (IND) became effective. However, FDA records indicate that the correct IND effective date was January 29, 1985, which was 30 days after FDA receipt of IND 27,645 on December 30, 1985.

2. The date the application was initially submitted with respect to the human drug product under section 505(b) of the Federal Food, Drug, and Cosmetic Act: July 11, 1994. The applicant claims July 8, 1994, as the date the new drug application (NDA) for ULTANETM (NDA 20–478) was initially submitted. However, FDA records indicate that the applicant submitted NDA 20–478 on July 8, 1994, and the agency received the NDA on July 11, 1994, which is considered to be the NDA initially submitted date.

3. The date the application was approved: June 7, 1995. FDA has verified the applicant's claim that NDA 20–478 was approved on June 7, 1995.

This determination of the regulatory review period establishes the maximum potential length of a patent extension. However, the U.S. Patent and Trademark Office applies several statutory limitations in its calculations of the actual period for patent extension. In its application for patent extension, this applicant seeks 1,826 days of patent term extension.

Anyone with knowledge that any of the dates as published is incorrect may, on or before February 5, 1996, submit to the Dockets Management Branch (address above) written comments and ask for a redetermination. Furthermore,